Matt Hoffman, Editorial Director for NeurologyLive, has covered medical news for MJH Life Sciences, NeurologyLive’s parent company, since 2017. He executive produces the NeurologyLive Mind Moments® podcast, and hosted the Medical World News show Deep Dive. Follow him on Twitter @byMattHoffman or email him at [email protected]
The Alnylam Pharmaceuticals agent, already approved for the treatment of polyneuropathy in those with hATTR amyloidosis, has now shown promise as a therapeutic option for patients with ATTR amyloidosis with cardiomyopathy.
During a Focused Topic Session at the 2022 Alzheimer’s Association International Conference, NeurologyLive® inquired with a panel of experts about the possibility of exploring a combination approach to Alzheimer disease as the future of treatment.
Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive® team.
The monoclonal antibody that preferentially targets Aß oligomers failed to meet either of its coprimary end points—despite favorable results over the placebo group—in individuals who were unimpaired but at risk for AD.
A cohort of more than 2000 older Latin American individuals reported a significant difference in cognitive symptoms when they underwent a positive life change during the early phase of the COVID-19 pandemic.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of the Alzheimer's Association.
After an investigative report published in Science called to question years of research around the existence of an amyloid oligomer known as Aß*56, debates about the amyloid hypothesis have been reignited in the Alzheimer community.
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Darin T. Okuda, MD, and Karin Cook. [LISTEN TIME: 55 minutes]
Get caught up on some of the latest news in Alzheimer disease and dementia, with data updates and expert insights, all in one place from the NeurologyLive® team.
The oral suspension, marked as Ztalmy by developer Marinus, is the first drug approval for cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (also known as CDD), given the greenlight in March. The agent is now available as of July 28, 2022.
Those with an optimal Life's Simple 7 score had roughly a 30% to 43% lower lifetime stroke risk than those with an inadequate Life's Simple 7 categorization, corresponding to almost 6 additional years of stroke-free life.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is headache and migraine.
Get caught up on some of the latest news in headache and migraine, with data updates and expert insights, all in one place from the NeurologyLive® team.
The Rapid Hyperdensity tool uses noncontrast CT scans to evaluate the hyperdense tissue volume during the identification and assessment of intracerebral hemorrhage.
Expected to be marketed as Lumryz by Avadel Pharmaceuticals, the extended-release oral suspension sodium oxybate’s final approval is pending the disposition of the REMS patent listed in the FDA’s Orange Book.
Jill Farmer, DO, MPH, director of the Parkinson’s Disease and Movement Disorder Program at Global Neuroscience Institute, spoke at length about the recent ATMRD Congress, the state of care for movement disorders, and her hopes for the horizon of therapy and treatment.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is neuromuscular disorders.
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Rajesh Pahwa, MD. [LISTEN TIME: 27 minutes]
Get caught up on some of the latest news in epilepsy and seizure disorders, with data updates and expert insights, all in one place from the NeurologyLive® team.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is stroke and cerebrovascular disease.
After 3 instances of clinically significant, transient hypotension—which resolved after treatment halt—recruitment for the trial of the investigational recombinant KLK1 tissue protein has been paused.
Those with the common thyroid disorder displayed a more than 80% increased risk of dementia, with a more than 3-fold increase in the risk among those requiring hormone replacement therapy.
Get caught up on some of the latest news in movement disorders, with data updates and expert insights, all in one place from the NeurologyLive® team.
Expert clinicians offer their insight on the sleep disorder landscape, the state of mental health in pediatric migraine, an inaugural movement disorders congress, a novel stroke rehabilitation tool, and psychedelics in cluster headache.
Rachel Alvarez and Gustavo Dziewczapolski, PhD, of Cure CMD spoke about the benefits of attending the biennial Scientific & Family Conference to learn more about congenital muscle diseases and interact with the patient community.
Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive® team.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is epilepsy and seizure disorders.
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Serena L. Orr, MD, MSc. [LISTEN TIME: 32 minutes]
Jean Hubble, MD, semi-retired neurologist and consultant, spoke with the PMD Alliance at the ATMRD Congress about the advances made in the field and her hopes for the future of therapeutics and clinical care.
The NeurologyLive® team assembled some of the best discussions with leaders in headache and migraine medicine following the 2022 American Headache Society (AHS) Annual Scientific Meeting.
